U.S. health regulators authorized Regeneron's antibody drug to treat non-hospitalized COVID-19 patients who are at high risk of developing severe disease. The FDA also granted emergency usage for Eli Lilly's drug to treat COVID-19. Both the drugs are authorized for people above 12 years of age and experiencing mild-moderate symptoms.
- In October, President Trump was treated with Regeneron's REGN-COV2, remdesivir, and dexamethasone, when he contracted coronavirus. He said, "They gave me Regeneron, and it was like, unbelievable. I felt good immediately".
- Of the patients with a high risk of disease progression, the FDA said that around 3% of patients who were administered Rengeron's drug visited the hospital for hospitalization and emergency treatment, compared to 9% of the placebo group. The trial was conducted on 799 non-hospitalized patients.
- Both Regeneron's drug and Eli Lilly's treatment are based on monoclonal antibodies, which bind the spikes in SARS-CoV2 to prevent the virus from entering our cells. Monoclonal antibodies act similarly to the natural immune system and are lab-made proteins.